CGC News & Events

Stock futures are markedly higher this morning as investors return from the weekend focused on a preliminary U.S.-Iran peace agreement that could reopen the Strait of Hormuz and significantly ease pressure on global energy markets.Brent crude has dropped to roughly three-month lows after the announced agreement, easing concerns about supply disruptions and helping reduce inflation fears that had weighed on stocks throughout the spring.AI-related stocks are rebounding after last week's volatility, supported by falling Treasury yields and renewed optimism that the Federal Reserve may not need to become more aggressive on rates if energy-driven inflation continues to cool. Investors are also closely watching the strong post-IPO performance of SpaceX, which has helped reignite enthusiasm.This week's key event is the Federal Reserve meeting under Chair Kevin Warsh. Markets overwhelmingly expect no change in interest rates, but traders will scrutinize the Fed's outlook for inflation, growth, and the possibility of future rate hikes. Falling oil prices have reduced some of the urgency around inflation concerns heading into the meeting.In pre-market trading, S&P 500 futures rose 1.29%, Nasdaq futures rose 2.08% and Dow futures rose 1.03%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -SpaceXup 6%, building on the advance seen after Friday's IPOParamount Skydanceup 3% after the Antitrust Division of the U.S. Department of Justice gave approval to the proposed acquisition of Warner Bros. DiscoveryNano Dimensionup 2% after entering into a non-binding term sheet for a proposed business combination with Infinite EpigeneticsRokuup 1% after announcing a definitive agreement under which Fox will acquire Roku for $160.00 per share in a combination of cash and Fox Class A common stock, valuing Roku at approximately $22B in enterprise valueUP AFTER EARNINGS -Comtechup 6%Coda Octopusup 7%DOWN AFTER EARNINGS -Canopy Growthdown 1%LOWER -Elicio Therapeuticsdown 62% after announcing its AMPLIFY-7P study did not meet its pre-specified primary DFS endpoint in the intent-to-treat populationTraws Pharmadown 17% after reporting that the planned test of tivoxavir marboxil in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory AgencyFoxdown 14% after announcing a definitive agreement under which Fox will acquire Roku for $160.00 per share in a combination of cash and Fox Class A common stockFiservdown 6% after noting Mike Lyons has stepped down as CEO and member of the board of directors to become CEO of Truist FinancialCheesecake Factorydown 1% after Northcoast downgraded the stock to Neutral, citing valuation

The company said, "The Company expects successful execution of its strategic priorities to drive net revenue growth across the business in the fiscal year ended March 31, 2027. Implementation of strengthened cultivation practices is projected to contribute to meaningful improvements in gross margin. Ongoing cost discipline, as well as a full year of the efficiencies implemented during FY2026, are expected to lead to reduced operating expense. As a result, the Company expects to reach positive adjusted EBITDA during FY2027. With MTL Cannabis integration activities ongoing in the first half of 2027, the year-over-year improvements are expected to be more pronounced in the second half of the fiscal year." "The significant strengthening of our balance sheet during fiscal 2026 reduces risk while expanding our strategic flexibility. We took meaningful steps to reduce costs and focus resources where they can drive the best returns, and these efforts are starting to be reflected in our financial results. We are confident we have the right strategy and financial model in place to achieve our goal of delivering positive Adjusted EBITDA during fiscal 2027," said Tom Stewart, CFO.

Reports Q4 revenue C$84.7M vs. C$78M last year. "In fiscal 2026, we reset the business, laid a disciplined foundation, and made deliberate investments, including acquiring MTL Cannabis, that will drive the next phase of growth. We modernized our approach to innovation, and our business structure was optimized around a clear strategy. Looking ahead, the opportunity in front of us is significant. As the leading medical cannabis business in Canada by revenue, we are well positioned to extend that leadership into Europe - a market we believe represents enormous long-term opportunity and one where our brands, products and relentless execution give us a real competitive edge. We enter fiscal 2027 with momentum, clarity, and a team that has proven it can execute," said Luc Mongeau, CEO.